Search

Displaying results 5111 - 5120 of 8412 in total
  1. Drug

    Pinoxepin

    go.drugbank.com/drugs/DB21397
    Experimental

    Pinoxepin has a monoisotopic molecular weight of 398.18 Da.

  2. Drug

    Ruzadolane

    go.drugbank.com/drugs/DB21444
    Experimental

    Ruzadolane has a monoisotopic molecular weight of 375.13 Da.

  3. Drug

    Oleic monoethanolamide

    go.drugbank.com/drugs/DB16495
    Investigational

  4. Drug

    Rosemary

    go.drugbank.com/drugs/DB14272
    Investigational

    It is not an approved drug.

  5. Drug

    RC118

    go.drugbank.com/drugs/DB18428
    Investigational

    RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.

  6. Drug

    Domofenogene zalfaparvovec

    go.drugbank.com/drugs/DB16810
    Investigational

    Domofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.

  7. Drug

    AT-GTX-502

    go.drugbank.com/drugs/DB17001
    Experimental

    AT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.

  8. Drug

    Tefidsogene civaparvovec

    go.drugbank.com/drugs/DB16789
    Investigational

    Tefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing. … It consists of an adeno-associated virus (AAV) type 2/6 vector and a zinc finger nuclease (ZFN) system that inserts a correct copy of the Iduronate 2-Sulfatase (IDS) gene into the albumin locus in hepatocytes

  9. Drug

    ECT-001 expanded cord blood

    go.drugbank.com/drugs/DB21745
    Investigational

    [L52013] It is being investigated in hematopoietic cell transplantation as ECT-001 expanded cord blood can demonstrate enhanced stem cell proliferation and engraftment compared to untreated UBCs.

  10. Drug

    Disitamab vedotin

    go.drugbank.com/drugs/DB17208
    Investigational

    Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.[A254721]